Secnidazole Under Review for Trichomoniasis
The sNDA is based on data from a phase 3 study that evaluated secnidazole in 147 adult female patients with trichomoniasis.
The sNDA is based on data from a phase 3 study that evaluated secnidazole in 147 adult female patients with trichomoniasis.
Data from the pivotal phase 3 trial demonstrated clinically and statistically significant microbiological cure compared with placebo at the test of cure visit.
Accelerated approval was based on the number of treated patients who became IgG antibody negative or who showed an at least 20% decrease in optical density on 2 different IgG antibody tests against antigens of T. cruzi.
The multicenter, double-blind, placebo-controlled study investigated the efficacy and safety of secnidazole in 147 adult females with trichomoniasis.
The Food and Drug Administration (FDA) has approved the first generic of Daraprim (pyrimethamine) tablets. Pyrimethamine, a folic acid antagonist, is indicated for the treatment of toxoplasmosis when used with a sulfonamide. The approved generic version of Daraprim has been granted to Cerovene Inc and will be supplied as 25mg tablets. Toxoplasmosis is a disease…
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. SAN FRANCISCO – For patients with progressive Acanthamoeba…
The Balamuthia mandrillaris amoeba got into her upper nasal cavity and then into her bloodstream, eventually reaching her brain, according to the study published in the December issue of the International Journal of Infectious Diseases.
During 2004 to 2016, 82 percent of all tickborne disease reports were Lyme disease
These tests are intended to screen samples from individual human donors, including volunteers who give whole blood and blood components, as well as living organ and tissue donors.
Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. It is already approved to treat visceral, mucosal and cutaneous leishmaniasis in patients aged ≥12 years; it is the first oral treatment for this rare tropical parasitic disease.